Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Operating Expenses (2016 - 2025)

Zevra Therapeutics' Other Operating Expenses history spans 9 years, with the latest figure at $148.3 million for Q2 2025.

  • For Q2 2025, Other Operating Expenses changed N/A year-over-year to $148.3 million; the TTM value through Dec 2025 reached $148.3 million, up 818.21%, while the annual FY2025 figure was $148.3 million, N/A changed from the prior year.
  • Other Operating Expenses reached $148.3 million in Q2 2025 per ZVRA's latest filing, up from -$20.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $148.3 million in Q2 2025 to a low of -$25.9 million in Q3 2023.
  • Average Other Operating Expenses over 5 years is $11.1 million, with a median of $1.0 million recorded in 2021.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 30332.2% in 2022, then plummeted 737.15% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $59000.0 in 2021, then surged by 30332.2% to $18.0 million in 2022, then plummeted by 234.29% to -$24.1 million in 2023, then rose by 14.35% to -$20.7 million in 2024, then skyrocketed by 818.21% to $148.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Other Operating Expenses are $148.3 million (Q2 2025), -$20.7 million (Q1 2024), and -$24.1 million (Q4 2023).